<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04902651</url>
  </required_header>
  <id_info>
    <org_study_id>OPM-G-H-2004</org_study_id>
    <nct_id>NCT04902651</nct_id>
  </id_info>
  <brief_title>HM242-Gel vs Comparator</brief_title>
  <official_title>A PROSPECTIVE, CONTROLLED, RANDOMIZED, OPEN-LABEL PREMARKET MULTICENTER STUDY OF THE PERFORMANCE OF THE HM242-GEL VS COMPARATOR IN PATIENTS UNDER THE CONDITION OF VENOUS LEG ULCER</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>B. Braun Ltd. Centre of Excellence Infection Control</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>B. Braun Ltd. Centre of Excellence Infection Control</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of the study is to demonstrate that the HM242-Gel performs at least&#xD;
      comparably to INTRASITE Gel with regard to wound healing.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 21, 2021</start_date>
  <completion_date type="Anticipated">February 2022</completion_date>
  <primary_completion_date type="Anticipated">October 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary objective of the study is to demonstrate that the HM242-Gel performs at least comparably to INTRASITE Gel with regard to wound healing.</measure>
    <time_frame>28 days</time_frame>
    <description>The primary variable is defined as the relative reduction of the wound area of a patient in percentage 28 days (4 weeks) after baseline. The wound size area is measured on site by the tracing method.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">142</enrollment>
  <condition>Venous Leg Ulcer</condition>
  <arm_group>
    <arm_group_label>HM242-Gel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Intrasite Gel</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>HM242-Gel</intervention_name>
    <description>HM242-Gel compared to Intrasite Gel in patients with a venous leg ulcer</description>
    <arm_group_label>HM242-Gel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Intrasite Gel</intervention_name>
    <description>HM242-Gel compared to Intrasite Gel in patients with a venous leg ulcer</description>
    <arm_group_label>Intrasite Gel</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Males or females of at least 18 years at the time of enrolment&#xD;
&#xD;
          2. The legal capacity and ability to understand the nature, risks, significance and scope&#xD;
             of the clinical trial and to determine his or her will accordingly&#xD;
&#xD;
          3. Signed form of consent, including the understanding of and willingness by the patient&#xD;
             to participate in the clinical study and ability to comply with study procedures and&#xD;
             study visit schedule&#xD;
&#xD;
          4. Patients must be willing to have all dressing changes performed by the wound&#xD;
             specialist, with no treatments at home&#xD;
&#xD;
          5. Presence of at least one venous ulcer of the lower leg extending through the full&#xD;
             thickness of the skin but not down to muscle, tendon or bone&#xD;
&#xD;
          6. Size of study ulcer ≥ 2cm² and ≤ 100cm² measured using the tracing method.&#xD;
&#xD;
          7. Presence of venous leg ulcer for at least 6 weeks, but not longer than 12 months&#xD;
&#xD;
          8. Ankle Brachial Pressure Index (ABI) &gt; 0.75&#xD;
&#xD;
          9. In the case of a female patient of childbearing potential, willingness to use highly&#xD;
             effective methods of contraception (failure rate of &lt; 1% when used consistently and&#xD;
             correctly);acceptable contraceptive measures in this trial are: combined pill and&#xD;
             progestin-only pill, contraceptive patch, ring or injection, Etonogestrel implant,&#xD;
             intrauterine device (IUD) (copper and Levonogestrel), male sterilization (vasectomy),&#xD;
             female sterilization (abdominal, laparoscopic, hysteroscopic), or sexual abstinence.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients kept in an institution due to an official or court order&#xD;
&#xD;
          2. Patients dependent on the Sponsor, Investigator or Site&#xD;
&#xD;
          3. Patients suspected of having SARS-CoV-2 infection or COVID-19 disease&#xD;
&#xD;
          4. Study ulcer judged by the Investigator to be caused by a medical condition other than&#xD;
             venous insufficiency&#xD;
&#xD;
          5. Study ulcer with signs and symptoms of infection, or under suspicion of cancer&#xD;
&#xD;
          6. Study ulcer under treatment with topical antimicrobials within past two weeks or&#xD;
             systemic antimicrobial treatment within past two weeks&#xD;
&#xD;
          7. In the case of heavily exuding ulcers, if in the opinion of Investigator the patient&#xD;
             is not suitable for treatment with gel&#xD;
&#xD;
          8. More than two venous leg ulcers or more than two chronic wounds&#xD;
&#xD;
          9. Dementia stage greater than 3 according to Reisberg&#xD;
&#xD;
         10. Known allergies against wound dressings used in the study&#xD;
&#xD;
         11. Known chronical skin diseases, dermatoses, or known allergies or other conditions&#xD;
             which might trigger dermatitis&#xD;
&#xD;
         12. Acute cases of substance use disorders (ICD-10 F1x.1 or F1x.2)&#xD;
&#xD;
         13. Buerger's disease&#xD;
&#xD;
         14. Participation in Medical Device trials less than 4 weeks ago or participation in Drug&#xD;
             trials less than six months ago&#xD;
&#xD;
         15. Terminally ill patients&#xD;
&#xD;
         16. Patients with poorly managed diabetes mellitus: absence of a glycated hemoglobin test&#xD;
             within the last 3 months or a result of HbA1c ≥ 8% not older than 3 months, or a major&#xD;
             diabetes-related incident within the past 4 weeks&#xD;
&#xD;
         17. Ulcers of diabetic origin&#xD;
&#xD;
         18. Patients under treatment with systemic corticosteroids, immunosuppressant, cytotoxic&#xD;
             chemotherapy, or radiotherapy&#xD;
&#xD;
         19. Presence of one or more medical conditions (other than venous insufficiency and&#xD;
             diabetes) as determined by medical history, which:&#xD;
&#xD;
               -  Is known to interfere with the wound healing process (e.g. arteriopathy,&#xD;
                  vasculitis, rheumatoid arthritis, systemic lupus erythematosus, other auto-immune&#xD;
                  diseases, cancer, immunodeficiency, severe lymphedema of the leg, thrombophilia)&#xD;
&#xD;
               -  In the opinion of the Investigator, would make the patient an inappropriate&#xD;
                  candidate for this venous ulcer healing study (e.g. malnutrition, hygiene,&#xD;
                  obesity)&#xD;
&#xD;
         20. Pregnant or lactating patients&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Joerg Brechbuehl</last_name>
    <phone>+41 58 258 50 00</phone>
    <email>joerg.brechbuehl@bbraun.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Thomas Frei</last_name>
    <phone>+41 58 258 50 00</phone>
    <email>thomas.frei@bbraun.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Sanatorium Profesora Arenbergera</name>
      <address>
        <city>Praha</city>
        <state>Praha 1</state>
        <zip>11000</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Petr Arenberger, Prof.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kožní ambulance Fialová, s.r.o.</name>
      <address>
        <city>Praha</city>
        <state>Praha 6</state>
        <zip>16000</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alena Fialová, MUDr</last_name>
      <phone>+420 734 415 067</phone>
      <email>alenka.fialova@seznam.cz</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Viliam Cibik</name>
      <address>
        <city>Pruské</city>
        <zip>018 52</zip>
        <country>Slovakia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Viliam Cibik, MUDr</last_name>
      <email>viliam.cibik@srcsk.sk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rudolf Suchy</name>
      <address>
        <city>Trenčín</city>
        <zip>911 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rudolf Suchy, MUDr</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Czechia</country>
    <country>Slovakia</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 21, 2021</study_first_submitted>
  <study_first_submitted_qc>May 21, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 26, 2021</study_first_posted>
  <last_update_submitted>July 20, 2021</last_update_submitted>
  <last_update_submitted_qc>July 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Varicose Ulcer</mesh_term>
    <mesh_term>Leg Ulcer</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

